[Clinical evaluation of chemotherapeutic agents in the treatment of primary liver cancer].
For the comparison of effect of FT-207 alone and FT-207 + MMC combination chemotherapy on primary hepatocellular carcinoma, 41 patients were entered into the trial. Thirty-two cases whose data were evaluable were studied by Koyama's classification. There was only one effective case (6.6%) in single agent group (15 cases) and 5 cases (29.4%) were effective in combination chemotherapy (17 cases). MMC combination chemotherapy was more effective on regression in size of hepatomegaly than FT-207 alone. By osaka group classification, 5 cases (33.3%) in single agent group (15 cases) were effective, and 10 cases in combination group (17 cases) (58.8%) were effective. The slight side effect often necessitated upon cessation of the treatment in 31 cases but the disappeared on cessation or by decrease of dose.
D000328:Adult; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives*; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage* / Q000009:adverse effects; D005641:Tegafur / Q000008:administration & dosage* / Q000009:adverse effects; D000509:alpha-Fetoproteins / Q000032:analysis
D008937:Mitomycins; D000509:alpha-Fetoproteins; D005641:Tegafur; D016685:Mitomycin; D005472:Fluorouracil